BioWorld

Jan. 21, 2019

View Archived Issues

Money raised by biotech: 2019 vs. 2018

Biopharma money raised: Jan. 1 - 17, 2019

Week in review

Week in Washington

Word on the street

Conference data: December 2018

Regulatory submissions, approvals and other actions: December 2018

Handing over the dealmaking torch, 2018 logs monster biopharma deals, paves the way for top M&As

Biopharma licensing deals signed in 2018 climbed to 1,364 and have a projected value of $119.54 billion, a four-year high for an industry still riding the immuno-oncology wave. Read More

The week's biggest gainers and losers

BioWorld stock report for public biotechnology companies

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...